These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Efficacy of setegis administration after transvesical adenomectomy]. Author: Gorilovskiĭ LM, Zingerenko MB, Lakhno DA. Journal: Urologiia; 2007; (6):61, 63-5. PubMed ID: 18649663. Abstract: We studied efficacy ofsetegis in different doses for therapy of lower urinary tract symptoms in patients after transvesical adenomectomy (TVAE). The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE. Compared to the controls, terazosin-treated patients improved urination more noticeably. Thus, alpha-adrenoblocker segetis is effective and safe in therapy of imperative voiding disorders with symptoms of urgent incontinence in patients after TVAE. Use of this drug can significantly contribute to successful postoperative rehabilitation of postadenomectomy patients. Setegis can be recommended for wide clinical practice.[Abstract] [Full Text] [Related] [New Search]